LORICRIN and melanoma: We have previously identified loss of AMLo (combined loss of AMBRA1 and loricrin in the epidermis overlying the tumour) as a novel independent prognostic biomarker in early‐stage melanoma and identified a functional role for AMBRA1 in epidermal homeostasis.8